 |
combinatorial regimen of LV305 (lentiviral vector encoding NY-ESO-1 gene) and G305 (NY-ESO-1 recombinant protein plus GLA-SE) |
|---|---|
| Trade Name | |
| Orphan Indication | Soft tissue sarcoma |
| USA Market Approval | USA |
| USA Designation Date | 2016-05-02 00:00:00 |
| Sponsor | Immune Design Corp.;1616 Eastlake Ave. E, Suite 310;Seattle, Washington, 98102 |
